Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Liu, S.F.

Search results

  • RSS Feed
(1 - 17 of 17)
Distribution of solids in the rings of the HD 163296 disk
Analysis of Integrated Radiographic Data From Two Long-Term, Open-Label Extension Studies of Adalimumab for the Treatment of Rheumatoid Arthritis
Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial
Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
Longterm Use of Adalimumab as Monotherapy Following Attainment of Low Disease Activity with Adalimumab plus Methotrexate
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate versus Methotrexate Alone
Analysis of Integrated Radiographic Data for Two Longterm, Open-Label Extension Studies of Adalimumab
Analysis of Integrated Radiographic Data for Two Long-Term, Open-Label Extension Studies of Adalimumab
Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES THAN WITH EITHER MONOTHERAPY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: 8-YEAR RESULTS OF AN OPEN-LABEL EXTENSION OF A PHASE 3 TRIAL
INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES IN PATIENTS WITH ADVANCED RHEUMATOID ARTHRITIS: ANALYSIS OF THE FINAL 10-YEAR RESULTS OF AN OPEN-LABEL EXTENSION OF A PHASE 3 TRAIL
Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial
Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial